Associated tags: Patient, Hospital, Therapy, CGT, Pharmaceutical industry, Fausto Pocar, Security (finance)
Locations: UNITED STATES, EUROPE, ASIA, NORTH AMERICA, CALIFORNIA, MIDDLE EAST, NEW YORK, MASSACHUSETTS, BELGIUM, WALLONIA, WHITE PLAINS, NY, US
University of California, Davis,
Partnership,
University,
CGT,
Therapy,
Gene,
California Institute for Regenerative Medicine,
Regents of the University of California,
Regenerative medicine,
Delaware General Corporation Law,
Hospital,
UC,
UC Davis Health Stadium,
Patient,
CIRM,
POC,
Pharmaceutical industry and DAVIS, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, and University of California, Davis (UC Davis) , today announce an agreement to roll out proprietary Orgenesis Mobile Processing Units and Labs™ (“OMPULs™”) at medical or academic institutions within the University of California system.
Key Points:
- and DAVIS, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, and University of California, Davis (UC Davis) , today announce an agreement to roll out proprietary Orgenesis Mobile Processing Units and Labs™ (“OMPULs™”) at medical or academic institutions within the University of California system.
- These units will enable point-of-care treatment via the development and manufacture of cell and gene therapies from Orgenesis, its partners, and UC Davis’ partners, subject to further agreements.
- Since joining the Orgenesis POCare Network in 2020 , UC Davis Health has been utilizing Orgenesis’ POCare Service Platform to develop and supply cell and gene products and therapies.
- The first collaboration involved scaling up and integrating UC Davis’ lentiviral vector process for localized development and processing of cell and gene therapies for treating patients.
Doctor of Philosophy,
Regenerative medicine,
Hospital,
Patient,
CGT,
Cell,
Metalmark Capital,
SCB,
International Society,
Fausto Pocar,
Pharmaceutical industry,
Medical device,
Labs GERMANTOWN, Md., May 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc .
Key Points:
- GERMANTOWN, Md., May 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc .
- (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), today announced that cell and gene therapy pioneer Claudia Zylberberg, PhD has been appointed as an independent board member and senior advisor of its Morgenesis LLC (“Morgenesis”) point-of-care (POCare) subsidiary.
- As founder, board member and former CEO of Akron Bio, Dr. Zylberberg has led Akron Bio to its leadership position among makers of cGMP-compliant ancillary materials, novel products, and tools for advanced and regenerative medicines.
- “We’re very proud to have Claudia join us to guide Morgenesis as it redefines the possibilities for delivering POCare therapies,” said Vered Caplan, CEO of Orgenesis.
GMP,
Cell biology,
University,
CGT,
Gene,
School of Medicine, University of Patras,
Hematology,
Curriculum,
Statistics,
Biomedical sciences,
Center for Cell and Gene Therapy,
Master of Science,
Student,
Patient,
Association de médiation sociale v Union locale des syndicats CGT,
Knowledge,
Nursing,
Pharmaceutical industry,
Cell Of the ten graduates, the majority received immediate offers and progressed their careers in the field, including 4 at theraCell Laboratories itself.
Key Points:
- Of the ten graduates, the majority received immediate offers and progressed their careers in the field, including 4 at theraCell Laboratories itself.
- Multiple approved CGTs have demonstrated that this new class of medicines can treat or even cure intractable diseases, typically with a single dose.
- New technologies like the Orgenesis Mobile Processing Units and Labs™ (“OMPULs™”) can reduce the heavy manual burden associated with centralized production.
- But as regulators expect to soon be approving dozens of CGT per year, the need for CGT expertise will continue to grow.
GERMANTOWN, Md., May 19, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announced that Vered Caplan, CEO of Orgenesis, will be participating in the Benchmark Company’s 3rd Annual Healthcare House Call Virtual 1x1 Conference, which will be held on Tuesday, May 23, 2023.
Key Points:
- GERMANTOWN, Md., May 19, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announced that Vered Caplan, CEO of Orgenesis, will be participating in the Benchmark Company’s 3rd Annual Healthcare House Call Virtual 1x1 Conference, which will be held on Tuesday, May 23, 2023.
- The conference offers its clients one-on-one and small-group virtual meetings with the management of over 40 small and mid-sized healthcare companies.
- To register, please contact: Michael Fiorini – Director, Institutional Equity Sales of The Benchmark Company at [email protected] or your Benchmark Company representative.
GMP,
Partnership,
CGT,
QC,
Lentivirus,
CDMO,
Association de médiation sociale v Union locale des syndicats CGT,
SCTbio,
Quality control,
Family,
Vaccine,
Central Europe,
Labs,
Fausto Pocar The goal of the collaboration is to open new point-of-care (POCare) sites within the Czech Republic and leverage SCTbio’s GMP facility for the production of lentivirus vectors to support Morgenesis’ POCare worldwide customers, including use in CAR-T cell and gene therapies (CGTs).
Key Points:
- The goal of the collaboration is to open new point-of-care (POCare) sites within the Czech Republic and leverage SCTbio’s GMP facility for the production of lentivirus vectors to support Morgenesis’ POCare worldwide customers, including use in CAR-T cell and gene therapies (CGTs).
- The POCare centers and OMPULs are designed to shorten the implementation time of new production, while offering a more cost-effective environment and enabling local scalability.
- SCTbio brings expertise in retroviral vector GMP production with a deep knowledge of state-of-the-art manufacturing technologies and quality control (QC) methods.
- Ludek Sojka, Chief Executive Officer at SCTbio, stated, “We are looking forward to collaborating with Orgenesis.
(NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the first quarter ended March 31, 2023.
Key Points:
- (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the first quarter ended March 31, 2023.
- Vered Caplan, CEO of Orgenesis, said, “We achieved revenue of approximately $7.0 million for the first quarter of 2023, which reflects the continued progress of our POCare strategy.
- We are currently focused on the implementation of our quality systems, as well as our GMP processes at the various POCare sites.
- We are also expanding our international management team with the support of Metalmark, our long-term partner and investor in our Morgenesis subsidiary.
CGT,
Securities and Exchange Commission of Pakistan,
CGMP,
Patient,
DSM-IV codes,
Growth,
Security (finance),
Metalmark Capital,
Therapy,
Fausto Pocar,
Pharmaceutical industry,
Management,
Metalmark This investment follows the previously announced investment of $30 million in November 2022.
Key Points:
- This investment follows the previously announced investment of $30 million in November 2022.
- In addition, Metalmark has committed to investing up to an additional $15 million, subject to the achievement of certain milestones.
- This additional investment will further propel our growth as we expand our global operations and add key personnel, enabling us to capitalize on the substantial demand for our POCare services.
- Morgenesis will use the additional capital to support the development of additional POCare Centers, as well as the OMPULs in both the U.S. and international markets.
The keynote series will be delivered at the INTERPHEX conference .
Key Points:
- The keynote series will be delivered at the INTERPHEX conference .
- This event covers the pharmaceutical product development lifecycle, between April 25-27, 2023, at the Javits Centre in New York.
- The Keynote Series will be held on the Innovation Stage, Booth #1378 on Wednesday, Apr 26, between 1:15 pm and 3:00 pm Eastern Time.
- The keynote series will cover how the bio and pharma industries can build on the successes of continuous manufacturing (CM) for the advanced manufacture of pharmaceuticals.
University of California, Davis,
University,
CGT,
Marketing,
Telephone,
UC,
Patient,
Investment,
MOU,
Pancreatectomy,
Security (finance),
FDA,
Therapy,
Pharmaceutical industry,
EU,
Labs,
Fausto Pocar GERMANTOWN, Md., March 21, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the fourth quarter and year ended December 31, 2022.
Key Points:
- (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the fourth quarter and year ended December 31, 2022.
- Vered Caplan, CEO of Orgenesis, said, “I am pleased to report that revenue for the fourth quarter of 2022 increased by 98% to $13.6 million, compared to $6.9 million for the same period last year as we are progressing with the planned rollout of our POCare platform.
- In addition to our strong revenue growth, we reduced our operating loss by 91% for the fourth quarter of 2022 versus the same period last year, which reflects our cost-effective and highly scalable business model.
- In 2022, our subsidiary, Koligo Therapeutics, supplied Kyslecel to five medical institutes supplying total pancreatectomy - islet auto transplant (TP-IAT) cases.
GERMANTOWN, Md., March 17, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc .
Key Points:
- GERMANTOWN, Md., March 17, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc .
- The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and using entry code 328506.
- A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2585/47900 or on the Company’s Investor Events section of the website here .
- A webcast replay will be available on the Company’s Investor Events section of the website ( https://ir.orgenesis.com/events#/ ) through Thursday, March 21, 2024.
